Skip to main content
SpringerLink
Log in

Therapeutic implications of the TGF-β system

  • Published:
Journal of Mammary Gland Biology and Neoplasia Aims and scope Submit manuscript

Abstract

This review considers the various roles of the TGF-β system in mammary carcinogenesis, tumor progression, and cellular responses to therapeutic measures. The paradigm that has evolved from the work of many investigators suggests that loss of tumor cell responsiveness to the effects of TGF-β can result in a crucial shift in the net effect of TGF-β within the context of the tumor-host interaction. Principal elements of host-tumor interactions in which this shift may play out, including immune suppression, angiogenesis, and modification of the surrounding extracellular matrix by tumor cells, are potentially amenable to manipulation. Additional effects of TGF-β, such as suggested by reports of its ability to alter the drug resistance of tumor cells and the drug sensitivity of normal tissues, suggest that appropriate molecular intervention designed to affect the TGF-β system might constitute an effective therapeutic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. D. F. Pierce, Jr., A. E. Gorska, A. Chytil, K. S. Meise, D. L. Page, R. J. Coffey, Jr., and H. L. Moses. (1995). Mammary tumor suppression by transforming growth factor β1 transgene expression.Proc. Natl. Acad. Sci. U.S.A 92:4254–4258.

    PubMed  Google Scholar 

  2. B. A. Arrick, M. Korc, and R. Derynck (1990). Differential regulation of expression of three transforming growth factor β species in human breast cancer cell lines by estradiol.Cancer Res. 50:299–303.

    PubMed  CAS  Google Scholar 

  3. M.-H. Jeng, P. Ten Dijke, K. K. Iwata, and V. C. Jordan (1993). Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells.Mol. Cell. Endocrinol. 97:115–123.

    PubMed  CAS  Google Scholar 

  4. T.-A. Dickens and A. A. Colletta (1993). The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer.Bio Essays 15:71–74.

    CAS  Google Scholar 

  5. D.M. Wiseman, P.J. Polverini, D. W. Kamp, and S. J. Leibovich (1988). Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity.Biochem. and Biophys. Res. Commun. 157:793–800.

    CAS  Google Scholar 

  6. N. Ueki, M. Nakazato, T. Ohkawa, T. Ikeda, Y. Amuro, T. Hada, and K. Higashino (1992). Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth.Biochim. Biophys. Acta Mol. Cell Res. 1137:189–196.

    CAS  Google Scholar 

  7. C. M. Gajdusek, Z. Luo, and M. R. Mayberg (1993). Basic fibroblast growth factor and transforming growth factor beta-1: Synergistic mediators of angiogenesis in vitro.J. Cell. Physiol. 157: 133–144.

    PubMed  CAS  Google Scholar 

  8. E. Y. Yang and H. L. Moses (1990). Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane.J. Cell Bio. 111:731–741.

    Article  CAS  Google Scholar 

  9. M. L. Iruela-Arispe and E. H. Sage (1993). Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-β1.J. Cell. Biochem. 52:414–430.

    PubMed  CAS  Google Scholar 

  10. F. Ruscetti, L. Varesio, A. Ochoa and J. Ortaldo (1993). Pleiotropic effects of transforming growth factor-β on cells of the immune system.Ann. NY Acad. Sci. 685:488–500.

    PubMed  CAS  Google Scholar 

  11. C. L. Arteaga, S. D. Hurd, A. R. Winnier, M. D. Johnson, B. M. Fendly, and J. T. Forbes (1993). Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression.J. Clin. Invest. 92:2569–2576.

    PubMed  CAS  Google Scholar 

  12. H. Fakjrai, O. Dorigo, D. L. Shawler, H. Lin, D. Mercola, K. L. Black, I. Royston, and R. E. Sobol (1996). Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy.Proc. Natl. Acad. Sci. U.S.A. 93:2909–2914.

    Article  PubMed  Google Scholar 

  13. N. Ueki, T. Ohkawa, Y. Yokoyama, J. Maeda, Y. Kawai, T. Ikeda, Y. Amuro, T. Hada, and K. Higashino (1993). Potentiation of metastatic capacity by transforming growth factor-β1 gene transfection.Jpn. J. Cancer Res. 84:589–593.

    PubMed  CAS  Google Scholar 

  14. S. M. Gorsch, V. A. Memoli, T. A. Stukel, L. I. Gold, and B. A. Arrick (1992). Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer.Cancer Res. 52:6949–6952.

    PubMed  CAS  Google Scholar 

  15. B. I. Dalal, P. A. Keown, and A. H. Greenberg (1993). Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.Am. J. Pathol. 143:381–389.

    PubMed  CAS  Google Scholar 

  16. A. Huang, H. Jin, and J. A. Wright (1995). Drug resistance and gene amplification potential regulated by transforming growth factor β1 gene expression.Cancer Res. 55:1758–1762.

    PubMed  CAS  Google Scholar 

  17. R. Strange, F. Li, S. Saurer, A. Burkhardt, and R. R. Friis (1992). Apoptotic cell death and tissue remodelling during mouse mammary gland involution.Development 115:49–58.

    PubMed  CAS  Google Scholar 

  18. D. K. Armstrong, J. T. Isaacs, Y. L. Ottaviano, and N. E. Davidson (1992). Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468.Cancer Res. 52:3418–3424.

    PubMed  CAS  Google Scholar 

  19. A. M. Warri, R. L. Huovinen, A. M. Laine, P. M. Martikainen, and P. L. Harkonen (1993). Apoptosis in toremifene-induced growth inhibition of human breast cancer cellsin vivo andin vitro.JNCI 85:1412–1418.

    PubMed  CAS  Google Scholar 

  20. R. Huovinen, A. Warri, and Y. Collan (1993). Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene.Int. J. Cancer 55:685–691.

    PubMed  CAS  Google Scholar 

  21. D. N. Danforth, Jr. and M. K. Sgagias (1996). Tumor necrosis factor α enhances secretion of transforming growth factor β2 in MCF-7 breast cancer cells.Clin. Cancer Res. 2:827–835.

    PubMed  Google Scholar 

  22. A. Butta, K. MacLennan, K. C. Flanders, N. P. M. Sacks, I. Smith, A. McKinna, M. Dowsett, L. M. Wakefield, M. B. Sporn, M. Baum, and A. A. Colletta (1992). Induction of transforming growth factor β1 in human breast cancerin vivo following tamoxifen treatment.Cancer Res. 52:4261–4264.

    PubMed  CAS  Google Scholar 

  23. P. A. Murray, J. Gomm, D. Ricketts, T. Powles and R. C. Coombes (1994). The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: An immunocytochemical study.Eur. J. Cancer 30A:1218–1222.

    Article  PubMed  CAS  Google Scholar 

  24. A. M. Thompson, D. J. Kerr, and C. M. Steel (1991). Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.Br. J. Cancer 63:609–614.

    PubMed  CAS  Google Scholar 

  25. M. S. Anscher, W. P. Peters, H. Reisenbichler, W. P. Petros, and R. L. Jirtle (1993). Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplatation for advanced breast cancer.N. Engl. J. Med. 328:1592–1598.

    PubMed  CAS  Google Scholar 

  26. T. Murase, M. S. Anscher, W. P. Petros, W. P. Peters, and R. L. Jirtle (1995). Changes in plasma transforming growth factor beta in response to hige-dose chemotherapy for stage II breast cancer: Possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity.Bone Marrow Trans. 15:173–178.

    CAS  Google Scholar 

  27. F.-M. Kong, M. S. Anscher, T. Murase, B. D. Abbott, J. D. Iglehart, and R. L. Jirtle (1995). Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor.Ann. Surg. 222:155–162.

    PubMed  CAS  Google Scholar 

  28. L. M. Wakefield, J. J. Letterio, T. Chen, D. Danielpour, R. S. H. Allison, L. H. Pai, A. M. Denicoff, M. H. Noone, K. H. Cowan, J. A. O'Shaughnessy, and M. B. Sporn (1995). Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.Clin. Cancer Res. 1:129–136.

    PubMed  CAS  Google Scholar 

  29. D. J. Grainger, D. E. Mosedale, J. C. Metcalfe, P. L. Weissberg, and P. R. Kemp (1995). Active and acid-activatable TGF-beta in human sera, platelets and plasma.Clin. Chim. Acta 235:11–31.

    PubMed  CAS  Google Scholar 

  30. P. Puolakkainen, D. Twardzik, J. Ranchalis, M. Moroni, J. Mandeli, and P. A. Paciucci (1995). Increase in plasma transforming growth factor beta (TGFβ) during immunotherapy with IL-2.Cancer Invest. 13:583–589.

    PubMed  CAS  Google Scholar 

  31. W. A. Border and N. A. Noble (1994). Transforming growth factor β in tissue fibrosis.N. Engl. J. Med. 331:1286–1292.

    PubMed  CAS  Google Scholar 

  32. M. H. Barcellos-Hoff, R. Derynck, M. L.-S. Tsang, and J. A. Weatherbee (1994). Transforming growth factor-β activation in irradiated murine mammary gland.J. Clin. Invest. 93:892–899.

    Article  PubMed  CAS  Google Scholar 

  33. K. Randall and J. E. Coggle (1995). Expression of transforming growth factor-β1 in mouse skin during the acute phase of radiation damage.Int. J. Radiat. Biol. 68:301–309.

    PubMed  CAS  Google Scholar 

  34. E. Clarke, G. C. Rice, R. S. Weeks, N. Jenkins, R. Nelson, J. A. Bianco, and J. W. Singer (1996). Lisofylline inhibits transforming growth factor β release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice.Cancer Res. 56:105–112.

    PubMed  CAS  Google Scholar 

  35. A. B. Roberts and M. B. Sporn (1992). Mechanistic interrelationships between two superfamilies: The steroid/retinoid receptors and transforming growth factor-β.Cancer Surv. 14:205–220.

    PubMed  CAS  Google Scholar 

  36. C. Jhappan, A. G. Geiser, E. C. Kordon, D. Bagheri, L. Hennighausen, A. B. Roberts, G. H. Smith, and G. Merlino (1993). Targeting expression of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation.EMBO J. 12:1835–1845.

    PubMed  CAS  Google Scholar 

  37. D. F. Pierce, Jr., M. D. Johnson, Y. Matsui, S. D. Robinson, L. I. Gold, A. F. Purchio, C. W. Daniel, B. L. M. Hogan, and H. L. Moses (1993). Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1.Genes Devel. 7:2308–2317.

    PubMed  CAS  Google Scholar 

  38. E. C. Kordon, R. A. McKnight, C. Jhappan, L. Hennighausen, G. Merlino, and G. H. Smith (1995). Ectopic TGF-β1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population.Devel. Biol. 168:47–61.

    Article  CAS  Google Scholar 

  39. E. Kalkhoven, B. A. Roelen, J. P. de Winter, C. L. Mummery, A. J. van den Eignden-van Raaji, P. T. Van der Saag, and B. Van der Burg (1995). Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines.Cell Growth Diff. 6:1151–1161.

    PubMed  CAS  Google Scholar 

  40. L. Sun, G. Wu, J. K. V. Willson, E. Zborowska, J. Yang, I. Rajkarunanayake, J. Wang, L. E. Gentry, X.-F. Wang, and M. G. Brattain (1994). Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells.J. Biol. Chem. 269:26449–26455.

    PubMed  CAS  Google Scholar 

  41. M. Younes, R. Fernandez, and R. Laucirica (1995). Transforming growth factor β receptor II (TGF-β-RII) is infrequently expressed in breast cancer.Proc. Am. Assoc. Cancer Res. 36:626.

    Google Scholar 

  42. K. Koli and C. L. Arteaga (1996). Predominant cytosolic localization of TGF-β-type II receptors in human breast carcinoma cells.Proc. Am. Assoc. Cancer Res. 37:37.

    Google Scholar 

  43. J. Taipale and J. Keski-Oja (1996). Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor-β1.J. Biol. Chem. 271:4342–4348.

    Article  PubMed  CAS  Google Scholar 

  44. A. B. Tuck, M. Park, E. E. Sterns, A. Boag, and B. E. Elliot (1996). Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.Am. J. Pathol. 148:225–232.

    PubMed  CAS  Google Scholar 

  45. F. J. Burrows, E. J. Derbyshire, P. L. Tazzari, P. Amlot, A. F. Gazdar, S. W. King, M. Letarte, E. S. Vitetta, and P. E. Thorpe (1995). Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.Clin. Cancer Res. 1:1623–1634.

    PubMed  CAS  Google Scholar 

  46. H. Yamashita, H. Ichijo, S. Grimsby, A. Moren, P. Ten Dijke, and K. Miyazono (1994). Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β.J. Biol. Chem. 269:1995–2001.

    PubMed  CAS  Google Scholar 

  47. K. Grzegorzewski, F. W. Ruscetti, N. Usui, G. Damia, D. L. Longo, J. A. Carlino, J. R. Keller, and R. H. Wiltrout (1994). Recombinant transforming growth factor β1 and β2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.J. Exp. Med. 180:1047–1057.

    Article  PubMed  CAS  Google Scholar 

  48. D. F. Pierce, Jr. and R. J. Coffey (1994). Therapeutic manipulation of cytokines: Transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine.Am. Surg. 60:18–25.

    PubMed  Google Scholar 

  49. S. T. Sonis, L. Lindquist, A. Van Vugt, A. A. Stewart, K. Stam, G.-Y. Qu, K. K. Iwata, and J. D. Haley (1994). Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3.Cancer Res. 54:1135–1138.

    PubMed  CAS  Google Scholar 

  50. H. J. Schluesener and R. Meyermann (1991). Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type β.Acta Neuropathol (Berl.) 81:641–648.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire

    Bradley A. Arrick

Authors
  1. Bradley A. Arrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arrick, B.A. Therapeutic implications of the TGF-β system. J Mammary Gland Biol Neoplasia 1, 391–397 (1996). https://doi.org/10.1007/BF02017395

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02017395

Key words

Search

Navigation